President Donald Trump has signed an executive order on improving Medicare.
President Donald Trump has signed an executive order on improving Medicare.
Speaking at the retirement center The Villages in Sumpter County, Florida, Trump said on Thursday that the order, titled “Protecting and Improving Medicare for Our Nation’s Seniors,” delivers on his campaign promise to defend the Medicare program.
“I made you a sacred pledge that I would strengthen, defend Medicare,” said Trump, and suggested that he was making good on his promise by signing “a very historic executive order” to ensure that Medicare “will never be taken away from you. We’re not letting anyone get close.”
The order itself claims that Democrats’ proposals to institute a “Medicare for All” system, which Trump called a “threat like never before,” would strip seniors of their choices and harm beneficiaries. “Instead of ending the current Medicare program and eliminating health choices for all Americans, my Administration will continue to protect and improve Medicare by building on those aspects of the program that work well, including the market-based approaches in the current system,” the order reads.
To achieve those goals, within 1 year, HHS will propose a regulation that will make it easier to obtain Medicare Medical Savings Accounts and include a payment model that adjusts Medicare Advantage (MA) benefits to allow beneficiaries to share in savings from the program through rebates. HHS Secretary Alex Azar will be required to outline an approach to changing Medicare fee-for-service (FFS) payments to more closely align with prices paid in MA, to propose regulation to give beneficiaries more access to providers and plans, and to propose regulations that will reduce burdens on providers and ensure appropriate reimbursement.
The order also calls for providing seniors with more information about healthcare quality and cost, eliminating waste and combatting fraud, and transitioning toward “true market-based pricing” in the FFS Medicare program, which will involve shared savings and competitive bidding.
In his remarks, Trump said that his administration is “lowering the cost of prescription drugs, taking on the pharmaceutical companies,” yet notably, the executive order did not include a provision to implement the administration’s proposed international price index (IPI) to reduce drug costs in Medicare.
In 2018, the administration released a plan to allow CMS to set prices for some drugs, including biologics and biosimilars, using prices paid in other countries as external references. While some stakeholders voiced concerns about the IPI model, the proposal did garner rare bipartisan interest, and in her own plan to lower drug prices for Medicare, House Speaker Nancy Pelosi, D-California, proposed a similar model that would cap drugs’ prices at 1.2 times the average selling price in Australia, Canada, France, Germany, Japan, and the United Kingdom. Also included in Pelosi’s plan is authorizing HHS to negotiate prices for up to 250 drugs that lack genereic or biosimilar competition.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.